Myocardial infarction with nonobstructive coronary arteries: Current management strategies

Kevin G Buda1, Sanjoyita Mallick2, Louis P Kohl3

  • 1Cardiology Division, Department of Internal Medicine, Hennepin Healthcare, Minneapolis, MN; Minneapolis Heart Institute and Abbott Northwestern Hospital, Minneapolis, MN.

PubMed

Insights

Myocardial infarction with nonobstructive coronary arteries (MINOCA) affects 6-8% of patients, often younger women. A collaborative, standardized diagnostic approach using cardiac MRI is needed to improve MINOCA patient outcomes.

Area of Science:

  • Cardiology
  • Cardiovascular Disease
  • Medical Diagnostics

Background:

  • A significant percentage of myocardial infarction (MI) cases, 6-8%, lack obstructive coronary artery disease on angiography.
  • This MINOCA subgroup often presents with distinct demographic profiles, including younger age and higher prevalence in women.

Purpose of the Study:

  • To present a diagnostic algorithm for identifying the causes of myocardial infarction with nonobstructive coronary arteries (MINOCA).
  • To advocate for a standardized, collaborative approach to MINOCA diagnosis and management for improved patient outcomes.

Main Methods:

  • Review of existing literature and proposed diagnostic strategies for MINOCA.
  • Emphasis on integrating cardiac magnetic resonance imaging (CMR) into the diagnostic pathway.
  • Highlighting the importance of comprehensive clinical evaluation.

Main Results:

  • A proposed algorithm to systematically identify underlying causes in MINOCA patients.
  • Demonstration of MINOCA's distinct patient characteristics (younger, more women).
  • The review underscores the need for tailored treatment strategies based on accurate diagnosis.

Conclusions:

  • A standardized diagnostic pathway is crucial for effective MINOCA management.
  • Collaborative efforts between clinicians are essential to improve outcomes for MINOCA patients.
  • Integrating advanced imaging like CMR can enhance diagnostic accuracy and treatment personalization.

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
1
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
1
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
455
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
520
Aortic Regurgitation IV: Nursing Management01:17

Aortic Regurgitation IV: Nursing Management

A nurse managing a patient with aortic regurgitation begins with a comprehensive assessment, including a review of the patient's medical history, family history, and lifestyle factors. During the cardiac examination, the nurse listens for heart sounds and checks for signs of valve abnormalities. The nurse also observes for symptoms such as dyspnea, orthopnea, and paroxysmal nocturnal dyspnea and assesses the patient's endurance and daily activity tolerance.Based on the findings, the nurse...
9